MedTrace Logo

Novel Clinical Target in Fragile X Syndrome

NCT04314856 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2022-11-15

No results posted yet for this study

Summary

Fragile X syndrome (FXS) is the most common genetic cause of autism spectrum disorder (ASD). The investigators wish to examine brain distribution of sigma-1 receptors in young adult males with FXS using 18F-FTC-146 PET. This project will study the distribution of sigma-1 receptors in 15 young (18-30 years) male adults with FXS compared to 5 healthy adult volunteers.

Conditions

  • Fragile X Syndrome (FXS)

Interventions

DRUG

18F-FTC-146

18F-FTC-146 is a PET radiopharmaceutical that can be used to determine sigma-1 receptor density.

Sponsors & Collaborators

  • Guido A. Davidzon, MD, SM

    lead OTHER

Principal Investigators

  • Guido Davidzon, MD SM · Stanford University

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-01-12
Primary Completion
2022-06-30
Completion
2022-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04314856 on ClinicalTrials.gov